A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
|ClinicalTrials.gov Identifier: NCT01245166|
Recruitment Status : Unknown
Verified November 2010 by Lotus Pharmaceutical.
Recruitment status was: Recruiting
First Posted : November 22, 2010
Last Update Posted : November 22, 2010
Information provided by:
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||June 2011|
|Estimated Study Completion Date :||December 2011|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Wang JS, Huang CN, Hung YJ, Kwok CF, Sun JH, Pei D, Yang CY, Chen CC, Lin CL, Sheu WH; acarbose/metformin fixed-dose combination study investigators. Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. Diabetes Res Clin Pract. 2013 Oct;102(1):16-24. doi: 10.1016/j.diabres.2013.08.001. Epub 2013 Aug 15.